Frequently Asked Questions Primary Indication: Diluent for intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma Approval Date: FDA Approval -- September 27, 1996 How Supplied: 10 mL single-use ampules, packaged 10 amps per box and 20 boxes per case National Drug Code: 55792-007-10 Shelf-life: 60 months from date of manufacture Storage: Store at controlled room temperature, 20°-25°C (68°C -77°F) Availability: By prescription from any licensed pharmaceutical supplier

What is the stability of methotrexate and cytarabine in Elliotts B® Solution? Methotrexate 3mg/mL and Cytarabine 2mg/mL reconstituted in Elliotts B® Solution and stored in glass vials with plastic syringes have demonstrated to be physically and chemically stable for at least 48 hours at both 4°C and 23°C. However, intrathecal administration of such admixtures should be completed within several hours of preparation, as Elliotts B® Solution does not contain any bacteriostatic preservatives. (Monograph Reference: Data on file)

How can I order Elliotts B® Solution? Please call 1-855-752-9317 or fax 1-855-752-9318. For email inquiries: ContactUs@LukareMedical.com

Literature List: Cancer Facts & Figures 1996. Atlanta, GA: American Cancer Society, Inc.; 1996. Miller BA, Ries LAG, Hankey BF et al (eds). Cancer Statistics Review: 1973-1990. Bethesda, MD: National Cancer Institute; 1993. National Institutes of Health publication 93-2789. Geiser CF, Bioshop Y, Jaffe N. Furman L, Traggis D, Frie E. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood. 1975;45 (2): 189-195. See monograph reference list for additional references.